William Blair Has Positive Estimate for TLX FY2025 Earnings

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) - Analysts at William Blair boosted their FY2025 earnings per share estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report issued to clients and investors on Tuesday, June 3rd. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $0.83 for the year, up from their previous estimate of $0.82. William Blair has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares' current full-year earnings is $0.24 per share.

Separately, Wedbush began coverage on Telix Pharmaceuticals Limited American Depositary Shares in a report on Thursday. They set an "outperform" rating and a $22.00 price target for the company.

Telix Pharmaceuticals Limited American Depositary Shares Trading Down 0.7%

Shares of TLX stock opened at $17.36 on Friday. The firm's fifty day moving average price is $16.76 and its two-hundred day moving average price is $16.83. Telix Pharmaceuticals Limited American Depositary Shares has a 1 year low of $13.61 and a 1 year high of $30.36.

Institutional Trading of Telix Pharmaceuticals Limited American Depositary Shares

An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA bought a new stake in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 26,939 shares of the company's stock, valued at approximately $451,000.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.